Biolegend, 302934, Ultra-LEAF™ Purified anti-human CD28 Antibody, 1mg

CD28 is a 44 kD disulfide-linked homodimeric type I glycoprotein. It is a member of the immunoglobulin superfamily and is also known as T44 or Tp44. CD28 is expressed on most T lineage cells, NK cell subsets, and plasma cells. CD28 binds both CD80 and CD86 using a highly conserved motif MYPPY in the CDR3-like loop. CD28 is considered a major co-stimulatory molecule, inducing T lymphocyte activation and IL-2 synthesis, and preventing cell death. In vitro studies indicate that ligation of CD28 on T cells by CD80 and CD86 on antigen presenting cells provides a costimulatory signal required for T cell activation and proliferation.
1mg
Verified Reactivity: Human, Cynomolgus, Rhesus
Reported Reactivity: Baboon, Capuchin Monkey, Chimpanzee, Pigtailed Macaque, Sooty Mangabey, Squirrel Monkey
Antibody Type: Monoclonal
Host Species: Mouse
Formulation: 0.2 µm filtered in phosphate-buffered solution, pH 7.2, containing no preservative.
Endotoxin Level: Less than 0.01 EU/µg of the protein (< 0.001 ng/µg of the protein) as determined by the LAL test.
Preparation: The Ultra-LEAF™ (Low Endotoxin, Azide-Free) antibody was purified by affinity chromatography.
Concentration: The antibody is bottled at the concentration indicated on the vial, typically between 2 mg/mL and 3 mg/mL. Older lots may have also been bottled at 1 mg/mL. To obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.
Storage & Handling: The antibody solution should be stored undiluted between 2°C and 8°C. This Ultra-LEAF™ solution contains no preservative; handle under aseptic conditions.
Application: FC - Quality tested IHC-F, Costim, FA - Reported in the literature, not verified in house
Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 1.0 µg per million cells in 100 µl volume or 100 µl of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.
Application Notes: The Ultra-LEAF™ Purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for highly sensitive assays.
Application References(PubMed link indicates BioLegend citation): Schlossman S, et al. Eds. 1995. Leucocyte Typing V. Oxford University Press. New York. Nunes J, et al. 1993. Biochem. J. 293:835. Calea-Lauri J, et al. 1999. J. Immunol. 163:62. Tazi A, et al. 1999. J. Immunol. 163:3511. (IHC) Marti F, et al. 2001. J. Immunol. 166:197. (Costim) Jeong SH, et al. 2004. J. Virol. 78:6995. (Costim) Rivollier A, et al. 2004. Blood 104:4029. (Costim) Scharschmidt E, et al. 2004. Mol. Cell Biol. 24:3860. (Costim) Sheng W, et al. 2007.Elsevier 580:6819. PubMed Mitsuhashi M. 2007. Clin Chem.53:148. PubMed Ye Z, et al. 2008. Infect. Immun. 76:2541. PubMed Magatti M, et al. 2008. Stem Cells 26:182. (FA) PubMed Yoshino N, et al. 2008. Exp. Anim. (Tokyo) 49:97. (FC) Berg M, et al. 2008. J Leukoc Biol. 83:853. (IP) PubMed Rout N, et al. 2010. PLoS One 5:e9787. (FC) Leonard JA, et al. 2011. J. Virol. 85:6867. PubMed Nomura T, et al. 2012. J. Virol. 86:6481. PubMed
Product Citations: Michaels YS, et al. 2022. Sci Adv. 8:eabn5522. PubMed Xiong H, et al. 2023. EBioMedicine. 90:104507. PubMed Piede N, et al. 2023. Cells. 12:. PubMed Solier S, et al. 2023. Nature. 617:386. PubMed Si W, et al. 2023. iScience. 26:106529. PubMed Issler M, et al. 2023. Methods Mol Biol. 2654:363. PubMed Lin W, et al. 2023. Commun Biol. 6:447. PubMed Jiang D, et al. 2023. Nat Commun. 14:3642. PubMed Chan W, et al. 2023. J Exp Med. :220. PubMed Zheng G, et al. 2021. Signal Transduct Target Ther. 6:236. PubMed Tocheva AS, et al. 2020. Curr Protoc Immunol. 130:e103. PubMed Glass MC, et al. 2022. Cell Rep. 39:110728. PubMed Suwittayarak R, et al. 2022. Int J Mol Sci. 23: . PubMed Vazquez-Lombardi R, et al. 2022. Immunity. 55:1953. PubMed Ogishi M, et al. 2023. J Exp Med. 220: . PubMed Zhang Y, et al. 2022. J Immunol Res. 2022:9003902. PubMed Zheng X, et al. 2022. Cells. 12: . PubMed Vondra S, et al. 2023. Cell Rep. 42:111977. PubMed Trefny MP, et al. 2023. Nat Commun. 14:86. PubMed Yen M, et al. 2022. Cell. 185:1414. PubMed Sungur CM, et al. 2022. J Clin Invest. Online ahead of print. PubMed Pozzetto B, et al. 2021. Nature. 600:701. PubMed Liu Y, et al. 2021. Immunol Cell Biol. 99:697. PubMed Yuan X, et al. 2022. J Extracell Vesicles. 11:e12235. PubMed Wu SY, et al. 2021. J Immunother Cancer. 9: . PubMed Amiad-Pavlov D, et al. 2021. Sci Adv. 7: . PubMed Romero-Olmedo AJ, et al. 2022. Nat Microbiol. 7:195. PubMed Nicolas P, et al. 2022. J Exp Med. 219:. PubMed Yi K, et al. 2022. Front Immunol. 12:802795. PubMed Bellini N, et al. 2022. iScience. 25:105234. PubMed Wang C, et al. 2021. Cell Stem Cell. . PubMed Zhao J, et al. 2021. Front Immunol. 12:658420. PubMed Kwon M, et al. 2020. Clin Cancer Res. 1644:26. PubMed Wei JL, et al. 2021. J Immunother Cancer. 9: . PubMed Vanshylla K, et al. 2022. Cell Host Microbe. 30:69. PubMed Naaber P, et al. 2022. Cell Rep Med. 3:100716. PubMed Wang J, et al. 2022. Nat Commun. 13:6866. PubMed Schofield DJ, et al. 2021. MAbs. 13:1857100. PubMed Blewett M, et al. 2016. Sci Transl Med. 8: 356ra119. PubMed Grandclaudon M, et al. 2019. Cell. 179:432. PubMed Jung Y, et al. 2021. Nat Commun. 12:3872. PubMed Lerrer S, et al. 2021. iScience. 24:103020. PubMed Camviel N, et al. 2022. J Immunother Cancer. 10:. PubMed Smith CM, et al. 2021. Biochem J. 478:3331. PubMed Chan W, et al. 2021. Immunohorizons. 5:117. PubMed Saragovi A, et al. 2020. Elife. 9:00. PubMed Gurusamy M, et al. 2021. Nat Commun. 12:6798. PubMed Williamson LM, et al. 2021. NPJ Precis Oncol. 5:103. PubMed Fuseini H, et al. 2022. Front Immunol. 12:796898. PubMed Glassman CR, et al. 2021. Cell. 184(4):983-999.e24. PubMed Lin M, et al. 2015. Immunol Lett. 165:26. PubMed Han K, et al. 2021. Nat Metab. 3:318. PubMed Kinloch NN, et al. 2021. Nat Commun. 12:165. PubMed Sadik A, et al. 2020. Cell. 1252:182. PubMed Wen T, et al. 2022. Cancer Immunol Res. 10:162. PubMed Dahal S, et al. 2022. Retrovirology. 19:18. PubMed Collins DR, et al. 2021. Immunity. 54:2372. PubMed McBrien JB, et al. 2020. Nature. 578:154. PubMed Sun T, et al. 2019. Haematologica. 105:661. PubMed Texler B, et al. 2021. Cell Mol Gastroenterol Hepatol. 13:383. PubMed Fang F, et al. 2021. Cell Rep. 37:109981. PubMed Wang T et al. 2018. Immunity. 49(3):504-514 . PubMed Hirschberger S, et al. 2021. EMBO Mol Med. 13:e14323. PubMed Si J, et al. 2020. Cancer Cell. 38(4):551-566.e11. PubMed Reuschl AK, et al. 2022. Cell Rep. 39:110650. PubMed Sabag B, et al. 2022. Cancers (Basel). 14:. PubMed Jiang J, et al. 2021. Front Immunol. 12:785549. PubMed Rousso-Noori L, et al. 2021. Nat Commun. 12:3615. PubMed Clayton KL, et al. 2021. Cell Host Microbe. 29(3):435-447.e9. PubMed Olafsdottir TA, et al. 2022. Commun Biol. 5:914. PubMed Zhu P, et al. 2022. Cell Commun Signal. 20:121. PubMed Niu M, et al. 2021. Cell Reports. 36(8):109611. PubMed Kotanides H, et al. 2020. Mol Cancer Ther. 988:19. PubMed Chen PM, et al. 2022. Sci Adv. 8:eabo4271. PubMed Davis-Marcisak EF, et al. 2021. Genome Med. 13:129. PubMed
RRID: AB_11150591 (BioLegend Cat. No. 302933) AB_11148949 (BioLegend Cat. No. 302934) AB_2616667 (BioLegend Cat. No. 302943) AB_2616668 (BioLegend Cat. No. 302944) AB_2800748 (BioLegend Cat. No. 302959) AB_2800749 (BioLegend Cat. No. 302960)
Structure: Ig superfamily, type I transmembrane glycoprotein, homodimer, 44 kD
Distribution: Mature T cells, thymocytes, NK cell subsets, plasma cells, EBV-positive B cells
Function: T cell costimulation
Ligand/Receptor: CD80, CD86
Cell Type: B cells, NK cells, Plasma cells, T cells, Thymocytes, Tregs
Biology Area: Costimulatory Molecules, Immunology
Molecular Family: CD Molecules
Antigen References: 1. Schlossman S, et al. Eds. 1995. Leucocyte Typing V. Oxford University Press. New York. 2. June CH, et al. 1994. Immunol. Today 15:321. 3. Linskey PS, et al. 1993. Annu. Rev. Immunol. 11:191.
Gene ID: 940
UniProt: View information about CD28 on UniProt.org
Clone: CD28.2
Regulatory Status: RUO
Workshop: V-CD28.05
Other Names: T44, Tp44
Isotype: Mouse IgG1, κ
Q: Do you guarantee that your antibodies are totally pathogen free?
A: BioLegend does not test for pathogens in-house aside from the GoInVivo™ product line. However, upon request, this can be tested on a custom basis with an outside, independent laboratory.
Q: Does BioLegend test each Ultra-LEAF™ antibody by functional assay?
A: No, BioLegend does not test Ultra-LEAF™ antibodies by functional assays unless otherwise indicated. Due to the possible complexities and variations of uses of biofunctional antibodies in different assays and because of the large product portfolio, BioLegend does not currently perform functional assays as a routine QC for the antibodies. However, we do provide references in which the antibodies were used for functional assays and we do perform QC to verify the specificity and quality of the antibody based on our strict specification criteria.
Q: Does BioLegend test each Ultra-LEAF™ antibody for potential pathogens?
A: No, BioLegend does not test for pathogens in-house unless otherwise indicated.  However, we can recommend an outside vendor to perform this testing as needed.
Q: Have you tested this Ultra-LEAF™ antibody for in vivo or in vitro applications?
A: We don't test our antibodies for in vivo or in vitro applications unless otherwise indicated. Depending on the product, the TDS may describe literature supporting usage of a particular product for bioassay. It may be best to further consult the literature to find clone specific information.